

Leadership change at Genetic Signatures

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company, advises that its Chief Executive Officer (“CEO”), Ms Allison Rossiter, has informed the Board that she will be leaving Genetic Signatures in late February 2026 to take on a role with a global pharmaceutical company.

The Board is initiating a search for a CEO to replace Ms Rossiter, and will implement interim arrangements to maintain continuity of leadership and operations. Dr. Jenny Harry and Ms. Anne Lockwood will support the management team during this period of transition, while the Company’s US-based Directors will provide support for U.S. sales activities.

Allison Rossiter, outgoing CEO of Genetic Signatures, said “It has been a privilege to lead Genetic Signatures through a period of significant transformation. I am grateful to the Board and my colleagues for their trust and support, and I am confident that the company is positioned for future success.”

Caroline Waldron, Chair of Genetic Signatures, said “On behalf of the Board, I want to acknowledge our appreciation of Allison Rossiter’s leadership and contributions over the past year, including lifting the skill set of the organisation and building a stronger foundation to realise product sales in the U.S. We wish her every success in her future endeavours.”

In parallel with the search for a CEO, the recruitment process for the previously announced CFO role is progressing. These leadership changes bring the opportunity to further strengthen the capabilities of the existing management team and renew our effort into advancing U.S. market opportunities while meeting the needs of all our customers.”

– END –

Announcement authorised for release by the Board of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Caroline Waldron

Chair Genetic Signatures

Email: caroline.waldron@geneticsignatures.com

Phone: 0403 247 523

About Genetic Signatures Limited: Genetic Signatures is a global molecular diagnostics company, specialising in detecting infectious diseases, using patented 3base® technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures’ unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.